Comparative Pharmacology
Head-to-head clinical analysis: CEFOTETAN versus CEFUROXIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTETAN versus CEFUROXIME.
CEFOTETAN vs CEFUROXIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking and leading to cell lysis.
1 to 2 g intravenously or intramuscularly every 12 hours. For severe infections, up to 2 g every 12 hours for 5-10 days.
250-500 mg orally twice daily; 750 mg-1.5 g IV/IM every 8 hours for moderate infections; 1.5 g IV/IM every 8 hours for severe infections.
None Documented
None Documented
Clinical Note
moderateCefotetan + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefotetan."
Clinical Note
moderateCefuroxime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefuroxime."
Clinical Note
moderateCefuroxime + Cimetidine
"Cefuroxime can cause a decrease in the absorption of Cimetidine resulting in a reduced serum concentration and potentially a decrease in efficacy."
Clinical Note
moderate3-4.5 hours (6-8 hours in renal impairment).
Terminal elimination half-life is 1.2 hours in adults with normal renal function (increased to 15-22 hours in severe renal impairment [CrCl <10 mL/min], requiring dose adjustment).
Renal (80-90% unchanged), biliary (small amount, up to 20% in bile), fecal (<5%).
Renal excretion of unchanged drug accounts for 80-90% of elimination via glomerular filtration and tubular secretion; biliary/fecal excretion is minimal (<10%).
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
Cefuroxime + Methantheline
"Cefuroxime can cause a decrease in the absorption of Methantheline resulting in a reduced serum concentration and potentially a decrease in efficacy."